$6995 | Single User
$13990 | Site License
$20985 | Enterprise License

Frontier Pharma: Cardiovascular Disease - Diverse First-in-Class Molecular Targets to Bridge Unmet Needs in Pulmonary Hypertension, Heart Failure and Atherosclerosis [Report Updated: 01-08-2017]

Published by GBI Research: 01 Aug 2017 | 116716 | In Stock

Introduction

Frontier Pharma: Cardiovascular Disease - Diverse First-in-Class Molecular Targets to Bridge Unmet Needs in Pulmonary Hypertension, Heart Failure and Atherosclerosis

Summary

The cardiovascular disease (CVD) therapy area encompasses a range of different diseases and conditions affecting the heart and/or blood vessels. The most crucial risk factors for CVD are hypertension and dyslipidemia, which accelerate the development of atherosclerotic plaque building up within blood vessels. As atheroma develops it causes the affected blood vessels to narrow, restricting blood flow to the body, brain or heart, depending on its location. It is also possible for the fibrous cap of this plaque to break off, triggering the coagulation cascade and causing a thrombus to form locally, which can completely occlude blood flow.

The treatments of CVD typically focus on prevention by controlling the risk factors of CVD. As such, the treatments usually fall within three categories: anti-hypertensives, which aim to alterblood pressure to within a normal range; anti-dyslipidemic drugs, which aim to modify lipid levels to a normal range; and anti-thrombotic drugs, which aim to either prevent a thrombus from formingby inhibiting the coagulation cascade or platelet aggregation.

There has been vast scientific innovation within the CVD therapeutics market over recent decades, particularly within the anti-dyslipidemia market, first with the introduction of statins such as Lipitor (atorvastatin), and more recently with the introduction of PCSK9 inhibitors. Innovation continues within the dyslipidemia pipeline, with a range of first-in-class molecular targets in the pipeline, including those that offer the promise of revolutionizing treatment by reversing the process of atherosclerosis.

Heart failure and pulmonary hypertension remain poorly treated, and are associated with poor prognosis. Heart failure in particular is associated with a five-year mortality rate of 50%. The large pipeline for heart failure includes a high proportion of first-in-class products relative to other CVD indications, and possesses the potential for breakthroughs in the treatment of this condition.

Scope

- With over 1,400 products in active development, the pipeline for CVD is extensive. Does current pipeline innovation hold the potential to change the CVD market in the near future?

- There are 320 first-in-class products in the CVD market that act on a novel molecular target thatis not present in an approved product across any indication in the pharmaceutical industry. Which of these hold the greatest potential to improve future disease treatment with regard to their molecular target?

- Analysis of the history of strategic consolidations revealed a modest level of deal activity in recent years, and a large number of first-in-class products not yet involved in any deals. How do deal frequency and value compare between target families and molecule types, and which first-in-class programs that have not yet been involved in a licensing or co-development deal appear to be particularly promising?

Reasons to buy

- Understand the current clinical and commercial landscape. This includes a comprehensive study of disease pathogenesis, diagnosis and prognosis, and the treatment options available.

- Visualize the composition of the CVD market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed. This knowledge allows a competitive understanding of gaps in the current market.

- Analyze the CVD pipeline and stratify by stage of development, molecule type and molecular target. There are strong signs in the pipeline that the industry is seeking novel approaches to treating CVD to overcome the unmet need in the market.

- Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising early-stage targets have been reviewed in greater detail.

- Identify commercial opportunities in the CVD deals landscape by analyzing trends in licensing and co-development deals, and analyzing a curated list of CVD therapies that have not yet been involved in deals, and may offer potential investment opportunities.

Table of Contents
for Frontier Pharma: Cardiovascular Disease - Diverse First-in-Class Molecular Targets to Bridge Unmet Needs in Pulmonary Hypertension, Heart Failure and Atherosclerosis [Report Updated: 01-08-2017]

  • 1 Table of Contents

    1 Table of Contents 2

    1.1 List of Tables 4

    1.2 List of Figures 4

    2 Executive Summary 6

    2.1 Robust pipeline with attempts to meet unmet need 6

    2.2 Drugs targeting apolipoproteins and elements of the reverse lipid transport pathway offer potential new therapies for the treatment of dyslipidemia and atherosclerosis 6

    2.3 Cardiovascular disease pipeline emphasizes move away from conventional areas towards targets related to transmembrane and extracellular signaling 6

    3 The Case for Innovation 7

    3.1 Growing Opportunities for Biologic Products 8

    3.2 Diversification of Molecular Targets 8

    3.3 Innovative First-in-Class Product Developments Remain Attractive 9

    3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 9

    3.5 Sustained Innovation in Cardiovascular Disease 10

    3.6 GBI Research Report Guidance 10

    4 Clinical and Commercial Landscape 11

    4.1 Cardiovascular Disease Overview 11

    4.2 Symptoms, Disease Staging and Prognosis 12

    4.2.1 Symptoms 12

    4.2.2 Prognosis 12

    4.3 Diagnosis 13

    4.3.1 Blood Pressure Test 13

    4.3.2 Tests for Dyslipidemia 14

    4.3.3 Imaging Tests 14

    4.3.4 Stress Testing 15

    4.4 Epidemiology 15

    4.5 Etiology and Pathophysiology 15

    4.5.1 Etiology 15

    4.5.2 Pathophysiology 17

    4.6 Management and Treatment of Cardiovascular Disease 20

    4.6.1 Pharmacological Intervention 20

    4.6.2 Non-pharmacological Intervention 25

    4.6.3 Unmet Need 26

    4.7 Overview of Marketed Products 27

    5 Assessment of Pipeline Product Innovation 29

    5.1 Overview 29

    5.2 Pipeline by Stage of Development and Molecule Type 29

    5.2.1 Cardiovascular Disease Overall 29

    5.2.2 Key Cardiovascular Indications 31

    5.3 Pipeline by Molecular Target 34

    5.3.1 Cardiovascular Disease 34

    5.3.2 Key Cardiovascular Indications 37

    5.4 Comparative Distribution of Programs between the Market and Pipeline by Molecular Target Class 38

    5.5 First-in-Class Programs Targeting Novel Molecular Targets 39

    5.5.1 Cardiovascular Disease 39

    6 Signaling Network and Innovation Alignment within Cardiovascular Disease 59

    6.1 Complexity of Signaling Networks in Cardiovascular Disease 59

    6.2 Signaling Pathways and First-in-Class Molecular Target Integration 59

    6.3 First-in-Class Matrix Assessment 60

    7 First-in-Class Target and Pipeline Program Evaluation 66

    7.1 Pipeline Programs Targeting Apelin Receptor 66

    7.2 Pipeline Programs Targeting Apolipoproteins (Apolipoprotein E, Apolipoprotein C-III and Apolipoprotein A-I) 67

    7.2.1 APOE 68

    7.2.2 APOCIII 70

    7.2.3 ApoA1 71

    7.3 Pipeline Programs Targeting Scavenger Receptor Class B Member 1 (SRB1) 74

    7.4 Pipeline Programs Targeting Cholesteryl Ester Transfer Protein (CETP) 77

    7.5 Pipeline Programs Targeting Glutamyl Aminopeptidase 80

    7.6 Pipeline Programs Targeting E-selectin 82

    7.7 Pipeline Programs Targeting Platelet Glycoproteins (Platelet Glycoprotein VI and Platelet Glycoprotein Ib Alpha Chain) 85

    7.7.1 Platelet Glycoprotein VI (GP6) 85

    7.7.2 Platelet Glycoprotein Ib Alpha Chain (GP1ba) 87

    7.8 Pipeline Programs Targeting Tissue Factor 88

    7.9 Conclusion 90

    8 Strategic Consolidations 91

    8.1 Industry-Wide First-in-Class Deals 91

    8.2 Licensing Deals 93

    8.2.1 Deals by Region, Value and Year 93

    8.2.2 Deals by Stage of Development and Value 94

    8.2.3 Deals by Molecule Type, Molecular Target and Value 95

    8.2.4 List of Deals with Disclosed Deal Values 97

    8.3 Co-development Deals 98

    8.3.1 Deals by Region, Value and Year 98

    8.3.2 Deals by Region, Year and Value 98

    8.3.3 Deals by Stage of Development and Value 99

    8.3.4 Deals by Molecule Type, Molecular Target and Value 100

    8.3.5 List of Deals with Disclosed Deal Values 102

    8.4 First-in-Class Programs with and without Prior Involvement in Licensing and Co-development Deals 102

    9 Appendix 106

    9.1 References 106

    9.2 Abbreviations 110

    9.3 Disease List 110

    9.3.1 Hypertension 110

    9.3.2 Dyslipidemia 110

    9.3.3 Heart failure 111

    9.3.4 Thrombosis 111

    9.3.5 CVD events 111

    9.3.6 Other 111

    9.4 Research Methodology 111

    9.4.1 Data integrity 111

    9.4.2 Innovative and meaningful analytical techniques and frameworks: 111

    9.4.3 Evidence based analysis and insight: 111

    9.5 Secondary Research 112

    9.5.1 Market Analysis 112

    9.5.2 Pipeline Analysis 112

    9.5.3 First-in-Class Matrix Assessment 112

    9.5.4 First-in-Class Target Profiles 112

    9.5.5 Licensing and Co-Development Deals 113

    9.6 Contact Us 113

    9.7 Disclaimer 113

List Of Tables
in Frontier Pharma: Cardiovascular Disease - Diverse First-in-Class Molecular Targets to Bridge Unmet Needs in Pulmonary Hypertension, Heart Failure and Atherosclerosis [Report Updated: 01-08-2017]

1.1 List of Tables

Table 1: Cardiovascular Disease Therapeutics Market, Systolic and Diastolic Blood Pressure Level and Corresponding Category 13

Table 2: Cardiovascular Disease Therapeutics Market, Total Cholesterol, LDL and HDL Levels and Corresponding Category 14

Table 3: Cardiovascular Disease Therapeutics Market, Global, Epidemiology of Cardiovascular Disease, Forecast 2017 15

Table 4: Cardiovascular Disease Therapeutics Market, Global, Key Features and Pipeline Activity of Apelin Receptor, 2017 66

Table 5: Cardiovascular Therapeutics Market, Global, Pipeline Programs Targeting Apelin Receptor ,2017 67

Table 6: Cardiovascular Disease Therapeutics Market, Global, Key Features of Apolipoprotein E, 2017 69

Table 7: Cardiovascular Disease Therapeutics Market, Global, Pipeline Programs Targeting Apolipoprotein E, 2017 69

Table 8: Cardiovascular Disease Therapeutics Market, Global, Key Features of Apolipoprotein-CIII, 2017 70

Table 9: Cardiovascular Disease Therapeutics Market, Global, Pipeline Programs Targeting Apolipoprotein-CIII, 2017 71

Table 10: Cardiovascular Disease Therapeutics Market, Global, Key Features of Apolipoprotein-A1, 2017 72

Table 11: Cardiovascular Disease Therapeutics Market, Global, Pipeline Programs Targeting Apolipoportein-A1, 2017 73

Table 12: Cardiovascular Disease Therapeutics Market, Global, Key Features of SRB1, 2017 75

Table 13: Cardiovascular Disease Therapeutics Market, Global, Pipeline Programs Targeting SRB1, 2017 76

Table 14: Cardiovascular Therapeutics Market, Global, Key Features of CETP, 2017 78

Table 15: Cardiovascular Disease Therapeutics Market, Global, Pipeline Programs Targeting CETP, 2017 78

Table 16: Cardiovascular Disease Therapeutics Market, Global, Key Features of Glutamyl Aminopeptidase, 2017 81

Table 17: Cardiovascular Disease Therapeutics Market, Global, Pipeline Programs Targeting Glutamyl Aminopeptidase, 2017 81

Table 18: Cardiovascular Disease Therapeutics Market, Global, Key Features and Pipeline Activity of E-selectin, 2017 82

Table 19: Cardiovascular Disease Therapeutics Market, Global, Pipeline Programs Targeting E-selectin, 2017 83

Table 20: Cardiovascular Disease Therapeutics Market, Global, Key Features and Pipeline Activity of Platelet Glycoprotein VI, 2017 86

Table 21: Cardiovascular Disease Therapeutics Market, Global, Pipeline Programs Targeting Platelet Glycoprotein VI, 2017 87

Table 22: Cardiovascular Disease Therapeutics Market, Global, Key Features and Pipeline Activity of Platelet Glycoprotein Ib Alpha Chain, 2017 88

Table 23: Cardiovascular Disease Therapeutics Market, Global, Pipeline Programs Targeting Platelet Glycoprotein Ib Alpha Chain, 2017 88

Table 24: Cardiovascular Disease Therapeutics Market, Global, Key Features of Tissue Factor, 2017 89

Table 25: Cardiovascular Disease Therapeutics Market, Global, Pipeline Programs Targeting Tissue Factor, 2017 90

List Of Figures, Charts and Diagrams
in Frontier Pharma: Cardiovascular Disease - Diverse First-in-Class Molecular Targets to Bridge Unmet Needs in Pulmonary Hypertension, Heart Failure and Atherosclerosis [Report Updated: 01-08-2017]

1.2 List of Figures

Figure 1: Cardiovascular Disease and Associated Indications, Global, US, Innovation Trends in Product Approvals, 1987-2014 8

Figure 2: Cardiovascular Disease and Associated Indications, US, Sales Performance of First-in-Class and Non-First-in-Class Products Post Marketing Approval, 2006-2013 9

Figure 3: Cardiovascular Disease and Associated Indications, Global, Cardiovascular Disease Market by Molecular Target, 2017 28

Figure 4: Cardiovascular Disease and Associated Indications, Global, Pipeline by Therapy Area, 2017 29

Figure 5: Cardiovascular Disease, Global, Pipeline by Stage of Development and Molecule Type, 2017 30

Figure 6: Hypertension, Dyslipidemia, Thrombotic events, and Heart Failure, Global, Pipelines by Stage of Development, 2017 32

Figure 7: Hypertension, Dyslipidemia, Thrombotic Events, and Heart Failure, Global, Pipelines by Molecule Type, 2017 33

Figure 8: Cardiovascular Disease, Global, Pipeline by Molecular Target, 2017 35

Figure 9: Cardiovascular Disease, Global, Pipeline by Molecular Target Breakdown, 2017 36

Figure 10: Hypertension, Dyslipidemia, Thrombotic Events, Heart Failure, Global, Pipelines by Molecular Target, 2017 38

Figure 11: Cardiovascular Disease, Global, Pipeline and Marketed Products by Molecular Target Class, 2017 39

Figure 12: Cardiovascular Disease, Global, Pipeline by Molecular Target Class, First-in-Class Status and Stage of Development, 2017 40

Figure 13: Cardiovascular Disease Therapeutics Market, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Pipeline Products by Stage of Development and Molecular Target (%), 2017 41

Figure 14: Cardiovascular Disease Therapeutics Market, Global, Ratio of First-in-Class Products to First-in-Class Targets by Stage of Development and Molecular Target, 2017 42

Figure 15: Cardiovascular Disease Therapeutics, Global, List of All First-in-Class Pipeline Programs, 2017 Part 1 44

Figure 16: Cardiovascular Disease Therapeutics, Global, List of All First-in-Class Pipeline Programs, 2017 Part 2 45

Figure 17: Cardiovascular Disease Therapeutics, Global, List of All First-in-Class Pipeline Programs, 2017 Part 3 46

Figure 18: Cardiovascular Disease Therapeutics, Global, List of All First-in-Class Pipeline Programs, 2017 Part 4 47

Figure 19: Cardiovascular Disease Therapeutics, Global, List of All First-in-Class Pipeline Programs, 2017 Part 5 48

Figure 20: Cardiovascular Disease Therapeutics, Global, List of All First-in-Class Pipeline Programs, 2017 Part 6 49

Figure 21: Cardiovascular Disease Therapeutics, Global, List of All First-in-Class Pipeline Programs, 2017 Part 7 50

Figure 22: Cardiovascular Disease Therapeutics, Global, List of All First-in-Class Pipeline Programs, 2017 Part 8 51

Figure 23: Cardiovascular Disease Therapeutics, Global, List of All First-in-Class Pipeline Programs, 2017 Part 9 52

Figure 24: Cardiovascular Disease Therapeutics, Global, List of All First-in-Class Pipeline Programs, 2017 Part 10 53

Figure 25: Cardiovascular Disease Therapeutics, Global, List of All First-in-Class Pipeline Programs, 2017 Part 11 54

Figure 26: Cardiovascular Disease Therapeutics, Global, List of All First-in-Class Pipeline Programs, 2017 Part 12 55

Figure 27: Cardiovascular Disease Therapeutics, Global, List of All First-in-Class Pipeline Programs, 2017 Part 13 56

Figure 28: Cardiovascular Disease Therapeutics, Global, List of All First-in-Class Pipeline Programs, 2017 Part 14 57

Figure 29: Cardiovascular Disease Therapeutics, Global, List of All First-in-Class Pipeline Programs, 2017 Part 15 58

Figure 30: Cardiovascular Disease Therapeutics Market, Global, First-in-Class Molecular Target Analysis Matrix for Hypertension, 2017 61

Figure 31: Cardiovascular Disease Therapeutics Market, Global, First-in-Class Molecular Target Analysis Matrix for Heart Failure, 2017 62

Figure 32: Cardiovascular Disease Therapeutics Market, Global, First-in-Class Molecular Target Analysis Matrix for Dyslipidemia, 2017 63

Figure 33: Cardiovascular Disease Therapeutics Market, Global, First-in-Class Molecular Target Analysis Matrix for Thrombosis, 2017 64

Figure 34: Cardiovascular Disease Therapeutics Market, Global, First-in-Class Molecular Target Analysis Matrix for Other Atherosclerotic Cardiovascular Disease Indications, 2017 65

Figure 35: Cardiovascular Disease Therapeutics Market, Global, Industry-Wide Deals by Stage of Development and First-in-Class Status, 2006-2017 91

Figure 36: Cardiovascular Disease Therapeutics Market, Global, Industry-Wide Licensing Deals by Deal Value, Upfront Payment Value, Stage of Development and First-in-Class Status, 2006-2017 92

Figure 37: Cardiovascular Disease Therapeutics, Global, Licensing Deals by Region, Value and Year, 2006-2017 94

Figure 38: Cardiovascular Disease Therapeutics, Global, Licensing Deals by Deal Value, Upfront Payment Value and Stage of Development, 2006-2017 95

Figure 39: Cardiovascular Disease Therapeutics, Global, Number and Aggregate Deal Value of Licensing Deals by Molecule Type and Molecular Target, 2006-2017 96

Figure 40: Cardiovascular Disease Therapeutics, Global, Licensing Deals with Disclosed Deal Values, 2006-2017 97

Figure 41: Cardiovascular Disease Therapeutics, Global, Co-development Deals by Region, Value and Year, 2006-2017 99

Figure 42: Cardiovascular Disease Therapeutics, Global, Co-development Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006-2017 100

Figure 43: Cardiovascular Disease Therapeutics, Global, Number and Aggregate Deal Value of Co-development Deals by Molecule Type and Molecular Target, 2006-2017 101

Figure 44: Cardiovascular Disease Therapeutics, Global, Co-development Deals with Disclosed Deal Values, 2006-2017 102

Figure 45: Cardiovascular Disease Therapeutics Market, Global, First-in-Class Pipeline Products with Prior Involvement in Licensing or Co-development Deals, 2017 Part 1 103

Figure 46: Cardiovascular Disease Therapeutics Market, Global, First-in-Class Pipeline Products with Prior Involvement in Licensing or Co-development Deals, 2017 Part 2 104

Figure 47: Cardiovascular Disease Therapeutics Market, Global, First-in-Class Pipeline Products with Prior Involvement in Licensing or Co-development Deals, 2017 Part 3 105

Additional Details

Publisher

GBI Research

Publisher Information

Reference

116716 |

Number of Pages

113

Report Format

PDF

GBI Research Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation
Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product In...
01 Sep 2016 by GBI Research USD $6,995 More Info
Frontier Pharma: Chronic, Acute and Neuropathic Pain - GPCR and Nerve Growth Factor-based therapies offer strong potential in difficult-to-treat subtypes
Frontier Pharma: Chronic, Acute and Neuropathic Pain - GPCR and Nerve Growth Factor-based therapies ...
01 Aug 2016 by GBI Research USD $6,995 More Info
Frontier Pharma: Diabetic Complications - Innovative and Diverse Neuropathies, Nephropathy and Retinopathies Pipelines Demonstrate Shift Towards Disease Modifying Therapies
Frontier Pharma: Diabetic Complications - Innovative and Diverse Neuropathies, Nephropathy and Retin...
01 Jun 2016 by GBI Research USD $6,995 More Info
Frontier Pharma: Hematological Cancers - Highly Innovative Pipeline Continues Trend towards Targeted, Patient-Specific Therapies
Frontier Pharma: Hematological Cancers - Highly Innovative Pipeline Continues Trend towards Targeted...
01 Jun 2016 by GBI Research USD $6,995 More Info
Frontier Pharma: Gastric Cancer - Early Stage Pipeline Innovation Shows Shift Towards Targeted mAbs
Frontier Pharma: Gastric Cancer - Early Stage Pipeline Innovation Shows Shift Towards Targeted mAbsS...
10 Mar 2016 by GBI Research USD $6,995 More Info
Frontier Pharma: Breast Cancer - First-in-Class Innovation Clustered Around Growth Factor Signalling Processes
Frontier Pharma: Breast Cancer - First-in-Class Innovation Clustered Around Growth Factor Signalling...
16 Feb 2016 by GBI Research USD $6,995 More Info
Frontier Pharma: Chronic Obstructive Pulmonary Disease (COPD) - Identifying and Commercializing First-in-Class Innovation
Frontier Pharma: Chronic Obstructive Pulmonary Disease (COPD) - Identifying and Commercializing Firs...
16 Dec 2015 by GBI Research USD $6,995 More Info
Frontier Pharma: Innovative Licensing Opportunities in Non-Hodgkin Lymphoma
Frontier Pharma: Innovative Licensing Opportunities in Non-Hodgkin LymphomaSummaryNon-Hodgkin Lympho...
06 Aug 2015 by GBI Research USD $6,995 More Info
Frontier Pharma: Asthma - Identifying and Commercializing First-in-Class Innovation
Frontier Pharma: Asthma - Identifying and Commercializing First-in-Class InnovationSummaryLarge and ...
01 May 2015 by GBI Research USD $6,995 More Info
Frontier Pharma: Duchenne Muscular Dystrophy and Becker Muscular Dystrophy - Identifying and Commercializing First-in-Class Innovation
Frontier Pharma: Duchenne Muscular Dystrophy and Becker Muscular Dystrophy - Identifying and Commerc...
01 May 2015 by GBI Research USD $6,995 More Info

This report is published by GBI Research

Download Free Report Summary PDF

Frontier Pharma: Cardiovascular Disease - Diverse First-in-Class Molecular Targets to Bridge Unmet Needs in Pulmonary Hypertension, Heart Failure and Atherosclerosis [Report Updated: 01-08-2017] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data